Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111657 · ClinicalTrials.gov registry record · Phase 2
Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
A Phase 2 study, sponsored by John Sundy.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00111657: Completed Phase 2 study, sponsored by John Sundy.
NCT00111657 is a Phase 2 study that has completed, run by John Sundy. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00111657, a Phase 2 study, has completed, sponsored by John Sundy.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether PEG-uricase (a chemically modified recombinant mammalian enzyme that degrades uric acid) is effective in controlling hyperuricemia in patients with chronic gout, who cannot tolerate, or have not responded adequately, to conventional therapy for gout. Funding Source - FDA OOPD
Interventions
- BIOLOGICAL Pegloticase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-12 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00111657 record still lists
NCT00111657 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which Pegloticase is the first listed.
NCT00111657 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00111657 about?
NCT00111657 is a clinical study titled "Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout". The purpose of this study is to determine whether PEG-uricase (a chemically modified recombinant mammalian enzyme that degrades uric acid) is effective in controlling hyperuricemia in patients with chronic gout, who cannot tolerate, or have not responded adequately, to conventional therapy for gout....
What is the current status of trial NCT00111657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-12. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00111657?
The interventions under investigation include: Pegloticase (BIOLOGICAL).
Who is sponsoring clinical trial NCT00111657?
This trial is sponsored by John Sundy, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00111657's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia